<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="editorial" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id>
<journal-title>Frontiers in Cellular and Infection Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell. Infect. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">2235-2988</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fcimb.2025.1630872</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cellular and Infection Microbiology</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Advances in tick-borne diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Teymournejad</surname>
<given-names>Omid</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/399877/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Sharma</surname>
<given-names>Aditya Kumar</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2116307/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kumar</surname>
<given-names>Deepak</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1500467/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Pathology, College of Medicine, University of Illinois at Chicago</institution>, <addr-line>Chicago, IL</addr-line>, <country>United States</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Office of Disease Control, Division of Laboratories, Illinois Department of Public Health</institution>, <addr-line>Chicago, IL</addr-line>, <country>United States</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Life Sciences, School of Biosciences and Technology, Galgotias University</institution>, <addr-line>Greater Noida, Uttar Pradesh</addr-line>, <country>India</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Center for Molecular and Cellular Biosciences, School of Biological, Environmental, and Earth Sciences, University of Southern Mississippi</institution>, <addr-line>Hattiesburg, MS</addr-line>, <country>United States</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited and Reviewed by: Jon Skare, Texas A&amp;M Health Science Center, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Omid Teymournejad, <email xlink:href="mailto:ot3@uic.edu">ot3@uic.edu</email>; Aditya Kumar Sharma, <email xlink:href="mailto:aditya.sharmaphd@gmail.com">aditya.sharmaphd@gmail.com</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>06</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>15</volume>
<elocation-id>1630872</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>05</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>05</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Teymournejad, Sharma and Kumar</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Teymournejad, Sharma and Kumar</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" journal-id="Front Cell Infect Microbiol" journal-id-type="nlm-ta" xlink:href="https://www.frontiersin.org/research-topics/58073/advances-in-tick-borne-diseases" ext-link-type="uri">Editorial on the Research Topic <article-title>Advances in tick-borne diseases</article-title>
</related-article>
<kwd-group>
<kwd>tick-borne diseases</kwd>
<kwd>severe fever with thrombocytopenia syndrome (SFTS)</kwd>
<kwd>multi-epitope vaccine</kwd>
<kwd>metalloprotease BcEnhancin</kwd>
<kwd>tick <italic>Ixodes ricinus</italic>
</kwd>
<kwd>
<italic>Bartonella henselae</italic>
</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="7"/>
<page-count count="3"/>
<word-count count="1449"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Molecular Bacterial Pathogenesis</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Tick-borne diseases have a long history, which begin with Victor Babes description of Texas cattle fever in 1888 caused by the protozoan parasite <italic>Babesia bigemina</italic> and transmitted by the tick <italic>Rhipicephalus annulatus</italic> (<xref ref-type="bibr" rid="B5">Vannier et&#xa0;al., 2015</xref>). In 1893, Theobald Smith and Frederick Kilborne provided the first experimental proof of tick-mediated transmission by demonstrating that <italic>Rhipicephalus annulatus</italic> ticks transmitted a protozoan parasite <italic>Babesia bigemina</italic> to cattle, establishing our foundational understanding about vector-borne disease (<xref ref-type="bibr" rid="B5">Vannier et&#xa0;al., 2015</xref>). In 1906, Rocky Mountain spotted fever, caused by <italic>Rickettsia rickettsii</italic> and transmitted by the Rocky Mountain wood tick (<italic>Dermacentor andersoni</italic>), was identified as the first recognized tick-borne rickettsial disease, marking a significant milestone in the advancement of vector biology research (<xref ref-type="bibr" rid="B6">Walker, 1985</xref>; <xref ref-type="bibr" rid="B3">Liu, 2015</xref>).</p>
<p>In 1975, a cluster of arthritis cases in Lyme, Connecticut linked to the tick <italic>Ixodes scapularis</italic> (previously <italic>Ixodes dammini</italic>) led to the identification of Lyme disease caused by the spirochete <italic>Borrelia burgdorferi</italic>. Lyme disease presents with symptoms ranging from fever and rash to severe joint and neurological complications if untreated, and it remains the most prevalent tick-borne disease in the United States, with approximately 500000 cases annually and an economic burden exceeding $1 billion (<xref ref-type="bibr" rid="B7">Williamson and Calabro, 1984</xref>; <xref ref-type="bibr" rid="B1">Anderson and Magnarelli, 1994</xref>). Recent decades have seen the emergence of new tick-borne diseases, including Anaplasmosis, Ehrlichiosis, Tick-borne Relapsing Fever, Powassan virus, and Crimean-Congo Hemorrhagic Fever (<xref ref-type="bibr" rid="B2">Ismail et&#xa0;al., 2022</xref>; <xref ref-type="bibr" rid="B4">Sharma et&#xa0;al., 2023</xref>). These diseases pose significant challenges due to gaps in understanding their biology, diagnostics and treatment. This editorial highlight research published in the Research Topic &#x201c;<italic>Advances in tick-borne diseases</italic>.&#x201d; (<xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Flowchart illustrating a brief history of tick-borne diseases and content of the editorial.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-15-1630872-g001.tif"/>
</fig>
<p>The Research Topic begins with a multicenter retrospective cohort study by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcimb.2025.1531880">Fang et&#xa0;al.</ext-link>, which aimed to identify risk factors associated with fatal outcomes and evaluate the efficacy of glucocorticoid therapy in patients with Severe Fever with Thrombocytopenia Syndrome (SFTS), a viral tick-borne disease. Using regression analyses and nomograms, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcimb.2025.1531880">Fang et&#xa0;al.</ext-link> identified old age, consciousness disturbance, low monocyte count, prolonged activated partial thromboplastin time and high viral load as predictors of fatal outcome of SFTS. The research paper concluded that high-dose glucocorticoid (GC) therapy should be used cautiously as relatively high doses and early GC therapy increase mortality in SFTS patients, while low-dose GC treatment in patients with severe symptoms and low aspartate aminotransferase levels improved survival. This predictive model aids in risk stratification and guides tailored GC therapy for SFTS patients.</p>
<p>In another work, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2025.1479862">Moradkasani et&#xa0;al.</ext-link> employed <italic>in silico</italic> strategies to develop a multi-epitope vaccine (MEV) against <italic>Francisella tularensis</italic>, a highly infectious tick-borne bacterium. Using subcellular localization tools and reverse vaccinology pipelines, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2025.1479862">Moradkasani et&#xa0;al.</ext-link> screened 1921 proteins and identified 12 vaccine candidates. In this study, authors proposed MEV designed for seven immunodominant epitopes from four outer membrane proteins (including two hypothetical proteins, an OmpA family protein, and PD40), which each having properties including increased antigenicity, solubility, thermostability and half-life. Additionally, the study proposed 10 novel drug targets involved in translation, methylation and porphyrin biosynthesis, providing broad treatment options against various <italic>F. tularensis</italic> strains and addressing limitations in current tularemia treatments.</p>
<p>Similarly, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcimb.2024.1494450">Fongsaran et&#xa0;al.</ext-link> characterized <italic>DvRelish</italic>, a Relish-type NF-&#x3ba;B transcription factor in the tick <italic>Dermacentor variabilis</italic>, and its role in immune defense against <italic>Rickettsia</italic> infection. The authors found an increased <italic>DvRelish</italic> expression in tick hemocytes during <italic>Rickettsia</italic> infection compared to control. Also, RNA interference-mediated knockdown of <italic>DvRelish</italic> led to an increased rickettsial loads at 48 hours post-infestation, underscoring the role of <italic>DvRelish</italic> in the tick immune response. These findings highlight <italic>DvRelish</italic> as a central regulator of tick immunity and suggest that NF-&#x3ba;B signaling significantly influences vector competence for <italic>Rickettsia</italic> spp.</p>
<p>Further, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcimb.2024.1486426">Gou et&#xa0;al.</ext-link> demonstrated that <italic>Bartonella henselae</italic>, a zoonotic tick-borne bacterium, evades host cell responses due to its ability to enter into a viable but nonculturable (VBNC) state under stress conditions, such as fever (38.8&#xb0;C for 19 days) or antibiotic exposure (4 days). Studies demonstrated that, despite losing culturability, VBNC cells remained viable and retained intact cellular structures, as evidenced by transmission electron microscopy. Notably, the proteomic data demonstrated that the proteins associated with host cell invasion and stress resistance are upregulated and proteins related to cell signaling and cellular processes were downregulated. Studies also showed that <italic>Bartonella henselae</italic> can survive hostile conditions by entering a VBNC state and this state contributes to drug resistance, host invasion, diagnostic and treatment challenges.</p>
<p>Next, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcimb.2024.1496925">Taragelova et&#xa0;al.</ext-link> summarized a 20-year surveillance study (1999&#x2013;2019) of <italic>Ixodes ricinus</italic> ticks across 16 locations in Slovakia, testing 17,249 questing ticks for <italic>Borrelia burgdorferi</italic> sensu lato (s.l.). The key findings of the study include an overall prevalence of 18.8%, with 15.1% of nymphs and 24.3% of adults testing positive. Nine species within the <italic>B. burgdorferi</italic> s.l. complex were identified, including <italic>Borrelia afzelii</italic>, <italic>B. garinii/B. bavariensis</italic>, <italic>B. valaisiana, B. lusitaniae</italic>, <italic>B. burgdorferi</italic> sensu stricto, <italic>B.</italic> sp<italic>ielmanii, B. bissettii</italic>, <italic>B. kurtenbachii</italic>. Out of these <italic>Borrelia afzelii</italic> (37.1%), <italic>B.garinii/B. bavariensis</italic> (24.7%), and <italic>B. valaisiana</italic> (15.4%) were the most frequent and found at all the study sites whereas <italic>B. lusitaniae</italic>, <italic>B. burgdorferi</italic> sensu stricto, <italic>B. bavariensis</italic> and <italic>B.</italic> sp<italic>ielmanii</italic> were found in four samples and <italic>B. bissettii</italic> and <italic>B. kurtenbachii</italic> were also recorded in single cases. Additionally, the infection rate of <italic>Borrelia burgdorferi</italic> s.l. varied across habitats, with the highest prevalence observed in natural environments and the lowest in urban settings. These findings underscore the importance of long-term surveillance to evaluate the influence of climatic and socioeconomic factors on the distribution of tick-borne diseases.</p>
<p>Towards understanding the significance of gut microbiota in determining tick vector competence and defining the vector competence, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcimb.2024.1476266">Hodzic et&#xa0;al.</ext-link> revealed that <italic>Bacillus cereus</italic> LTG-1, an environmentally acquired gut bacterium in <italic>Ixodes ricinus</italic>, impairs <italic>Borrelia afzelii</italic> colonization through a secreted metalloprotease referred as <italic>BcEnhancin</italic>. Oral administration of <italic>B. cereus</italic> LTG-1 or purified <italic>BcEnhancin</italic> degraded the glycan-rich peritrophic matrix in the tick gut, which reduce <italic>B. afzelii</italic> load. Additionally, qRT-PCR data revealed that <italic>myd88</italic> and <italic>peritrophin 1</italic> genes were upregulated after 48 h of administration of recombinant BcEnhancin. Both genes are linked to immune system and peritrophic matrix in the tick gut respectively. These findings highlight the tick gut microbiome&#x2019;s role in shaping vector competence and offer new insights into the interactions among <italic>Borrelia</italic>, ticks, and their resident microbes.</p>
<p>In a similar direction, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcimb.2024.1450353">Guizzo et&#xa0;al.</ext-link> investigated the immune response of <italic>Ixodes ricinus</italic> ticks following exposure to either the Gram-positive bacterium <italic>Micrococcus luteus</italic> or the Gram-negative <italic>Pantoea</italic> sp. Although the tick midgut harbors a limited and inconsistent microbiota about which our understanding remains incomplete, the ticks were able to rapidly clear artificial infections with both <italic>M. luteus</italic> and <italic>Pantoea</italic> sp. Transcriptomic and proteomic analyses revealed several constitutively expressed antimicrobial peptides including defensins, amidase effectors, lysozymes, and gamma interferon-inducible lysosomal thiol reductases (GILTs). Antimicrobial activity assays confirmed that defensins 1 and 8 are highly effective against Gram-positive bacteria such as <italic>Micrococcus luteus</italic>. These findings suggest that a pre-existing and multi-component antimicrobial system in the tick midgut plays a central role in rapidly eliminating invading microbes.</p>
<p>Lastly, the editorial concludes with the study by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpubh.2024.1302133">Duan et&#xa0;al.</ext-link>, who investigated tick-borne bacteria and their associated infections in Arxan, Inner Mongolia, China, by analyzing 282 <italic>Ixodes persulcatus</italic>, 13 <italic>Dermacentor silvarum</italic> ticks, and 245 human blood samples. Using 16S rDNA sequencing and species-specific PCR, the authors detected <italic>Candidatus Rickettsia tarasevichiae</italic> (89%) and <italic>Borrelia garinii</italic> (17%) as the most prevalent pathogens in <italic>I. persulcatus</italic>, with 13% coinfection. In human samples, <italic>B. garinii</italic> (4.9%), <italic>Rickettsia slovaca</italic> (0.82%), and <italic>Coxiella burnetii</italic> (0.41%) were detected, with seroprevalence for spotted fever group rickettsiae (SFGR) and <italic>B. burgdorferi</italic> at 5.71% and 13.47%, respectively. The study confirmed <italic>B. garinii</italic> transmission from ticks to humans and reported the first detection of <italic>B. miyamotoi</italic> (7%) in ticks and <italic>R. slovaca</italic> (0.82%) in humans in Arxan, highlighting the need for ongoing surveillance.</p>
<p>Overall, we believe that collection of research articles featured in this Research Topic advance our understanding of tick-borne diseases by elucidating pathogen biology, vector competence, and host immune responses. From predictive models for SFTS treatment to innovative vaccine strategies for <italic>Francisella tularensis</italic> and insights into tick microbiome interactions, these findings pave the way for improved diagnostics, therapeutics, and prevention strategies. As tick-borne diseases continue to emerge and expand due to environmental and climatic changes, sustained research and surveillance are critical to mitigate their global public health impact.</p>
</body>
<back>
<sec id="s1" sec-type="author-contributions">
<title>Author contributions</title>
<p>OT: Project administration, Data curation, Writing &#x2013; original draft, Conceptualization, Supervision, Methodology, Investigation, Writing &#x2013; review &amp; editing, Validation, Formal Analysis. AS: Data curation, Validation, Project administration, Formal Analysis, Methodology, Investigation, Conceptualization, Writing &#x2013; review &amp; editing, Supervision, Writing &#x2013; original draft. DK: Supervision, Validation, Conceptualization, Methodology, Investigation, Visualization, Writing &#x2013; review &amp; editing, Formal Analysis, Project administration.</p>
</sec>
<sec id="s2" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research and/or publication of this article.</p>
</sec>
<sec id="s3" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s4" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<sec id="s5" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname> <given-names>J. F.</given-names>
</name>
<name>
<surname>Magnarelli</surname> <given-names>L. A.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Lyme disease: a tick-associated disease originally described in Europe, but named after a town in Connecticut</article-title>. <source>Am. Entomologist</source> <volume>40</volume>, <fpage>217</fpage>&#x2013;<lpage>228</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/ae/40.4.217</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ismail</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Sharma</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Soong</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Walker</surname> <given-names>D. H.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Review: protective immunity and immunopathology of ehrlichiosis</article-title>. <source>Zoonoses</source> <volume>2</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.15212/ZOONOSES-2022-0009</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>D.</given-names>
</name>
</person-group> (<year>2015</year>). &#x201c;<article-title>Rickettsia</article-title>,&#x201d; in <source>Molecular Medical Microbiology</source> (<publisher-loc>Amsterdam, Netherlands</publisher-loc>: <publisher-name>Elsevier</publisher-name>), <fpage>2043</fpage>&#x2013;<lpage>2056</lpage>.</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname> <given-names>A. K.</given-names>
</name>
<name>
<surname>Dhasmana</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Arora</surname> <given-names>G.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Bridging the gap: exploring the connection between animal and human health</article-title>. <source>Zoonotic Dis.</source> <volume>3</volume>, <fpage>176</fpage>&#x2013;<lpage>178</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/zoonoticdis3020014</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vannier</surname> <given-names>E. G.</given-names>
</name>
<name>
<surname>Diuk-Wasser</surname> <given-names>M. A.</given-names>
</name>
<name>
<surname>Ben Mamoun</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Krause</surname> <given-names>P. J.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Babesiosis</article-title>. <source>Infect. Dis. Clin. North Am.</source> <volume>29</volume>, <fpage>357</fpage>&#x2013;<lpage>370</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.idc.2015.02.008</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walker</surname> <given-names>D. H.</given-names>
</name>
</person-group> (<year>1985</year>). <article-title>Rickettsiae</article-title>.</citation>
</ref>
<ref id="B7">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Williamson</surname> <given-names>P. K.</given-names>
</name>
<name>
<surname>Calabro</surname> <given-names>J. J.</given-names>
</name>
</person-group> (<year>1984</year>). &#x201c;<article-title>Lyme disease&#x2014;a review of the literature</article-title>,&#x201d; in <source>Seminars in arthritis and rheumatism</source> (<publisher-loc>Amsterdam, Netherlands</publisher-loc>: <publisher-name>Elsevier</publisher-name>), <fpage>229</fpage>&#x2013;<lpage>234</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>